WallStreetZenWallStreetZen

NASDAQ: RXRX
Recursion Pharmaceuticals Inc Stock

$9.34+0.49 (+5.54%)
Updated Jun 24, 2024
RXRX Price
$9.34
Fair Value Price
N/A
Market Cap
$2.22B
52 Week Low
$4.97
52 Week High
$16.75
P/E
-5.77x
P/B
5.53x
P/S
50.9x
PEG
N/A
Dividend Yield
N/A
Revenue
$46.24M
Earnings
-$354.11M
Gross Margin
10.7%
Operating Margin
-776.37%
Profit Margin
-765.9%
Debt to Equity
0.39
Operating Cash Flow
-$317M
Beta
2.12
Next Earnings
Aug 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A

RXRX Overview

Recursion Pharmaceuticals Incorporated is a clinical-stage biotechnology company that integrates technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company is developing REC-994, which is in Phase IIa clinical trials to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trials to treat GM2 gangliosidosis. Recursion Pharmaceuticals was incorporated in 2013 and is headquartered in Salt Lake City, UT.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RXRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

RXRX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RXRX is good value based on its book value relative to its share price (5.53x), compared to the US Biotechnology industry average (6.29x)
P/B vs Industry Valuation
RXRX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RXRX due diligence checks available for Premium users.

Be the first to know about important RXRX news, forecast changes, insider trades & much more!

RXRX News

Valuation

RXRX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.77x
Industry
-6.96x
Market
30.03x

RXRX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
5.53x
Industry
6.29x
RXRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

RXRX's financial health

Profit margin

Revenue
$13.8M
Net Income
-$91.4M
Profit Margin
-662.4%
RXRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RXRX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$557.8M
Liabilities
$156.7M
Debt to equity
0.39
RXRX's short-term assets ($343.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RXRX's short-term assets ($343.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RXRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$102.3M
Investing
-$6.7M
Financing
$13.9M
RXRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

RXRX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
RXRX$2.22B+5.54%-5.77x5.53x
JANX$2.24B+5.52%-35.72x3.42x
VCEL$2.24B+2.64%N/A9.60x
RCKT$2.18B+7.03%-8.44x4.95x
APGE$2.28B+2.63%-7.43x2.84x

Recursion Pharmaceuticals Stock FAQ

What is Recursion Pharmaceuticals's quote symbol?

(NASDAQ: RXRX) Recursion Pharmaceuticals trades on the NASDAQ under the ticker symbol RXRX. Recursion Pharmaceuticals stock quotes can also be displayed as NASDAQ: RXRX.

If you're new to stock investing, here's how to buy Recursion Pharmaceuticals stock.

What is the 52 week high and low for Recursion Pharmaceuticals (NASDAQ: RXRX)?

(NASDAQ: RXRX) Recursion Pharmaceuticals's 52-week high was $16.75, and its 52-week low was $4.97. It is currently -44.22% from its 52-week high and 87.93% from its 52-week low.

How much is Recursion Pharmaceuticals stock worth today?

(NASDAQ: RXRX) Recursion Pharmaceuticals currently has 237,663,668 outstanding shares. With Recursion Pharmaceuticals stock trading at $9.34 per share, the total value of Recursion Pharmaceuticals stock (market capitalization) is $2.22B.

Recursion Pharmaceuticals stock was originally listed at a price of $31.30 in Apr 16, 2021. If you had invested in Recursion Pharmaceuticals stock at $31.30, your return over the last 3 years would have been -70.16%, for an annualized return of -33.18% (not including any dividends or dividend reinvestments).

How much is Recursion Pharmaceuticals's stock price per share?

(NASDAQ: RXRX) Recursion Pharmaceuticals stock price per share is $9.34 today (as of Jun 24, 2024).

What is Recursion Pharmaceuticals's Market Cap?

(NASDAQ: RXRX) Recursion Pharmaceuticals's market cap is $2.22B, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Recursion Pharmaceuticals's market cap is calculated by multiplying RXRX's current stock price of $9.34 by RXRX's total outstanding shares of 237,663,668.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.